Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.

Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.

Detalles Bibliográficos
Main Authors:	Bafadhel, M, Davies, L, Calverley, P, Aaron, S, Brightling, C, Pavord, I
Formato:	Journal article
Idioma:	English
Publicado:	European Respiratory Society 2014

Títulos similares

Blood Eosinophils and outcomes in severe hospitalized exacerbations of COPD
por: Bafadhel, M, et al.
Publicado: (2016)

Inhaled glucocorticoids and COPD exacerbations.
por: Brightling, C, et al.
Publicado: (2015)

Prednisolone response in patients with COPD.
por: Pavord, I, et al.
Publicado: (2004)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
por: Shrimanker, R, et al.
Publicado: (2017)

Blood eosinophil count and exacerbation risk in patients with COPD.
por: Kerkhof, M, et al.
Publicado: (2017)

Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population
por: Helen F. Ashdown, et al.
Publicado: (2021-02-01)

COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils
por: Eltboli, O, et al.
Publicado: (2014)

Seasonality of eosinophilic and non-eosinophilic exacerbations of COPD
por: Barker, R, et al.
Publicado: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
por: Moran, AM, et al.
Publicado: (2020)

Eosinophils in COPD: just another biomarker?
por: Bafadhel, M, et al.
Publicado: (2017)

Characterising non-eosinophilic COPD
por: Hambleton, K, et al.
Publicado: (2015)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
por: Siddiqui, S, et al.
Publicado: (2018)

Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations
por: Djamin, R, et al.
Publicado: (2019)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
por: Siddiqui SH, et al.
Publicado: (2018-11-01)

Association between blood eosinophil count and risk of exacerbations in patients with COPD
por: Kerkhof, M, et al.
Publicado: (2017)

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
por: Siva, R, et al.
Publicado: (2007)

Shall we focus on the eosinophil to guide treatment with systemic corticosteroids during acute exacerbations of COPD?: PRO
por: Camp, J, et al.
Publicado: (2018)

Prednisolone for COPD exacerbations: time for a rethink
por: Sanjay Ramakrishnan
Publicado: (2023-09-01)

Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of COPD?: PRO
por: James Camp, et al.
Publicado: (2018-09-01)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
por: Shrimanker, R, et al.
Publicado: (2017)

Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis
por: Bafadhel, M, et al.
Publicado: (2017)

Relationship Between Blood Eosinophils and Systemic Corticosteroid Therapy in COPD Exacerbation
por: Gong Y, et al.
Publicado: (2022-09-01)

Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
por: Bafadhel, M, et al.
Publicado: (2012)

Investigating blood eosinophil count thresholds in patients with COPD
por: Russell, R, et al.
Publicado: (2018)

Variability of blood eosinophil count and prognosis of COPD exacerbations
por: Sandra Martínez-Gestoso, et al.
Publicado: (2021-01-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
por: Shrimanker, R, et al.
Publicado: (2017)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
por: Bafadhel, M, et al.
Publicado: (2018)

Peripheral blood eosinophil drop-to-drop variation in patients with COPD using near patient testing: a small validation study
por: Jeffers, H, et al.
Publicado: (2017)

COPD exacerbations in general practice: variability in oral prednisolone courses
por: de Vries Marianne, et al.
Publicado: (2012-01-01)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
por: Moran, A, et al.
Publicado: (2020)

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations
por: Claus F. Vogelmeier, et al.
Publicado: (2019-08-01)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
por: Haldar, P, et al.
Publicado: (2009)

Aspergillus fumigatus during stable state and exacerbations of COPD.
por: Bafadhel, M, et al.
Publicado: (2014)

Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations.
por: Barker, B, et al.
Publicado: (2015)

Mepolizumab for eosinophilic COPD
por: Sciurba, F, et al.
Publicado: (2018)

Blood eosinophil levels as a biomarker in COPD
por: Brusselle, G, et al.
Publicado: (2018)

Copd in the ed: eosinophils, treatment and outcomes, data from the pre-award study
por: Russell, R, et al.
Publicado: (2016)

The significance of eosinophilic inflammation in COPD
por: Cooper, C, et al.
Publicado: (2017)

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
por: Green, R, et al.
Publicado: (2002)

Neutrophil-to-lymphocyte ratio, blood eosinophils and COPD exacerbations: a cohort study
por: Jens Ellingsen, et al.
Publicado: (2021-12-01)